Perinatal MortalityNCT03398551
Machine Learning From Fetal Flow Waveforms to Predict Adverse Perinatal Outcomes
An observational study of Perinatal Mortality and Neonatal Morbidities, run by Aga Khan University.
Trial summary
The aim of this study is to get a proof of concept for using a computational model of fetal haemodynamics, combined with machine learning based on Doppler patterns of the fetal cardiovascular, cerebral and placental flows, to identify those at increased risk of adverse perinatal outcomes such as stillbirth, perinatal… Read more about this study
- Who is it for?
- Any age, women onlyHealthy volunteers can take part
- Conditions the study is for
- Perinatal Mortality, Neonatal Morbidities
- How many people
- 525 participants
- Where
- No sites listed yet
- Study dates
- Feb 2018to Dec 2018
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- Women only
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: Pregnant women between 22-34 weeks who reside in Ibrahim Hyderi Goth which is a peri-urban settlement of approximately 70,000 on the south east of Karachi. It is one of the seven union councils in Bin Qasim town which has a population of one million.
Who may be able to join
- Pregnant woman coming to the ultrasound clinic between 22-34 weeks of gestation.
- Written informed consent
- Resident of the study area
Who cannot join
- Multiple gestation
- Known congenital anomaly in the fetus or newborn
- Refusal for the ultrasound
- Poor echocardiographic images for Doppler acquisition
Trial locations and contacts
No sites are listed yet.
About this study
The aim of this study is to get a proof of concept for using a computational model of fetal haemodynamics, combined with machine learning based on Doppler patterns of the fetal cardiovascular, cerebral and placental flows, to identify those at increased risk of adverse perinatal outcomes such as stillbirth, perinatal mortality and other neonatal morbidities.
We will also compare the sensitivity and specificity of UmbiFlow device with the machine learning model in predicting adverse perinatal outcomes
Read the detailed description
Pakistan is one of the countries where stillbirth rate (43/1000 total births) and neonatal mortality rate (55/1000 live births) are among the highest in the world. The figures for perinatal mortality remained unchanged between Pakistan Demographic and Health Survey (PDHS) 1990-91 and PDHS 2012-13. It is hence important to evaluate new techniques to identify high-risk pregnant women who can then subsequently receive personalized care to improve perinatal outcomes. Fetal blood flow waveforms assessed via Doppler ultrasound to indicate wellbeing of the fetus have been in practice for nearly four decades. Abnormal blood flow patterns in the fetal circulation detected by Doppler ultrasound may indicate poor fetal prognosis. These tracings will then be incorporated in a computational model and combined with machine learning, will be used to predict adverse perinatal outcomes.
This will be a prospective one group cohort study for a period of twelve months which will be based in Ibrahim Hyderi, a peri-urban settlement of approximately 70,000 on the south east of Karachi. The sample size for this study has been calculated based on the outcomes of the pregnancy and was estimated to be 525 pregnant women.
Recruitment - Household surveillance will be done by community health workers (CHWs) in the catchment area in a sequential manner to identify pregnant women. Eligible women between 22-34 weeks of gestation on last menstrual period (LMP) will then be explained regarding the purpose of the study and invited for an ultrasound scan.
First and enrollment visit - The first visit window for the ultrasound scan will be between 22-26 weeks of gestation. This window is selected because pregnancies at risk may be better identified and also visualization of fetal cardiac flow is possible. Based on the rigorous surveillance, we anticipate that most women will be in this window. The following information will be collected:
- Socio-demographic information
- Medical history, including exposure to tobacco, gravidity, parity, past obstetric history (including number of miscarriages, stillbirths or neonatal deaths) and comorbid conditions (pre-eclampsia, diabetes mellitus)
- Maternal anthropometry (height, weight and mid-upper arm circumference)
- Maternal blood pressure
- Hemoglobin of the mother
- Symphysiofundal height will be measured
- Standard obstetric Doppler evaluation including the four primary ultrasound measures of fetal growth-head circumference, biparietal diameter, abdominal circumference, and femur length is routinely performed for all pregnant women presenting at the center. These parameters will be used to estimate fetal weight (automatically calculated by the machine).
- Focused Fetal Doppler Echocardiography - These would include transabdominal measurements of the Doppler velocity of the umbilical artery, the middle cerebral artery (MCA), ductus arteriosus, fetal aortic isthmus (AoI) and left and right ventricular outflow tracts
- UmbiFlow - Umbilical artery continuous wave Doppler image will also be obtained on these women. The device will generate graphs for the flow pattern and calculate the resistance index for the flow.
Second visit - The second visit window of ultrasound scan will be between 30-34 weeks of gestation. This will be applicable for all women who have had their first scan during 22-26 weeks of gestation as well as newly enrolled women during 30-34 weeks of gestational age. Cardiotocography (CTG) will be performed for all recruited women during the second visit followed by the Doppler examination. The same procedures as described in the first visit will be done.
Follow up - We will obtain contact information (phone number) from all enrolled women. A trained research midwife will be responsible for making phone calls, as well as performing household visits at pre-specified intervals for immediate and early identification of the pregnancy outcome. A team of CHWs will perform home visits to the baby at post-natal day 1 and 6 and questions related to delayed cry, neonatal sepsis and hospital course (if any) will be collected and the weight and length of the baby will be recorded.
Verbal autopsy - The VA team will visit the family after the grieving period (at least 14 days after the death). VA will be performed using a structured tool (http://www.who.int/healthinfo/statistics/WHO_VA_2012_RC1_Instrument.pdf ).
- Conditions
- Perinatal Mortality, Neonatal Morbidities
- Keywords
- pregnancy, machine learning, fetal Doppler echocardiography
- Medical subject headings
- Perinatal Death
What is being measured
The primary outcome is the main question the study is designed to answer.
Stillbirth
Baby born with no signs of life at or after 28 weeks of gestation
Measured: At birth
Early neonatal mortality
Death of a baby within the first 7 days of life
Measured: Within the first 7 days of life
Secondary outcomes (5)
IUGR
Fetal weight that is below the 10th percentile for gestational age as determined through an ultrasound
Measured: At birth
Prematurity
Birth of a fetus at < 37 weeks of gestation
Measured: At birth
Birth asphyxia
Delayed cry after at least 1 minute of life
Measured: At birth
Neonatal sepsis
Any 1 of the following danger signs: fever > 38 of < 35.5 C, convulsions, lethargy, poor feeding, chest in drawing and tachypnea (respiratory rate > 60/min)
Measured: Within the first 7 days of life
Low Birth Weight
Birth weight < 2.5 kg
Measured: At birth
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jan 2018
- Study startFeb 2018 (estimated)
- Primary completionSep 2018 (estimated)
- Study completionDec 2018 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Perinatal MortalityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 525 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Aga Khan University
- Sponsor type
- University, hospital or other
- Collaborators
- Universitat Pompeu Fabra
- Responsible party
- Principal investigator, Zahra Hoodbhoy, Aga Khan University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03398551
- Sponsor's protocol ID
- 4872-Ped-ERC-17
- Status last verified
- Jan 2018
- First submitted
- 6 Jan 2018
- Last updated
- 12 Jan 2018
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 12 Jan 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Machine Learning From Fetal Flow Waveforms to Predict Adverse Perinatal Outcomes
- ClinicalTrials.gov ID
- NCT03398551
- Acronym / sponsor ID
- 4872-Ped-ERC-17
- Conditions
- Perinatal Mortality, Neonatal Morbidities
- Keywords
- pregnancy, machine learning, fetal Doppler echocardiography
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 525 participants (estimated)
- Lead sponsor
- Aga Khan UniversityUniversity, hospital or other
- Collaborators
- Universitat Pompeu Fabra
- Study start
- Feb 2018 (estimated)
- Primary completion
- Sep 2018 (estimated)
- Study completion
- Dec 2018 (estimated)
- First posted
- 12 Jan 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to get a proof of concept for using a computational model of fetal haemodynamics, combined with machine learning based on Doppler patterns of the fetal cardiovascular, cerebral and placental flows, to identify those at increased risk of adverse perinatal outcomes such as stillbirth, perinatal mortality and other neonatal morbidities.
We will also compare the sensitivity and specificity of UmbiFlow device with the machine learning model in predicting adverse perinatal outcomes
Detailed description
Pakistan is one of the countries where stillbirth rate (43/1000 total births) and neonatal mortality rate (55/1000 live births) are among the highest in the world. The figures for perinatal mortality remained unchanged between Pakistan Demographic and Health Survey (PDHS) 1990-91 and PDHS 2012-13. It is hence important to evaluate new techniques to identify high-risk pregnant women who can then subsequently receive personalized care to improve perinatal outcomes. Fetal blood flow waveforms assessed via Doppler ultrasound to indicate wellbeing of the fetus have been in practice for nearly four decades. Abnormal blood flow patterns in the fetal circulation detected by Doppler ultrasound may indicate poor fetal prognosis. These tracings will then be incorporated in a computational model and combined with machine learning, will be used to predict adverse perinatal outcomes.
This will be a prospective one group cohort study for a period of twelve months which will be based in Ibrahim Hyderi, a peri-urban settlement of approximately 70,000 on the south east of Karachi. The sample size for this study has been calculated based on the outcomes of the pregnancy and was estimated to be 525 pregnant women.
Recruitment - Household surveillance will be done by community health workers (CHWs) in the catchment area in a sequential manner to identify pregnant women. Eligible women between 22-34 weeks of gestation on last menstrual period (LMP) will then be explained regarding the purpose of the study and invited for an ultrasound scan.
First and enrollment visit - The first visit window for the ultrasound scan will be between 22-26 weeks of gestation. This window is selected because pregnancies at risk may be better identified and also visualization of fetal cardiac flow is possible. Based on the rigorous surveillance, we anticipate that most women will be in this window. The following information will be collected:
- Socio-demographic information
- Medical history, including exposure to tobacco, gravidity, parity, past obstetric history (including number of miscarriages, stillbirths or neonatal deaths) and comorbid conditions (pre-eclampsia, diabetes mellitus)
- Maternal anthropometry (height, weight and mid-upper arm circumference)
- Maternal blood pressure
- Hemoglobin of the mother
- Symphysiofundal height will be measured
- Standard obstetric Doppler evaluation including the four primary ultrasound measures of fetal growth-head circumference, biparietal diameter, abdominal circumference, and femur length is routinely performed for all pregnant women presenting at the center. These parameters will be used to estimate fetal weight (automatically calculated by the machine).
- Focused Fetal Doppler Echocardiography - These would include transabdominal measurements of the Doppler velocity of the umbilical artery, the middle cerebral artery (MCA), ductus arteriosus, fetal aortic isthmus (AoI) and left and right ventricular outflow tracts
- UmbiFlow - Umbilical artery continuous wave Doppler image will also be obtained on these women. The device will generate graphs for the flow pattern and calculate the resistance index for the flow.
Second visit - The second visit window of ultrasound scan will be between 30-34 weeks of gestation. This will be applicable for all women who have had their first scan during 22-26 weeks of gestation as well as newly enrolled women during 30-34 weeks of gestational age. Cardiotocography (CTG) will be performed for all recruited women during the second visit followed by the Doppler examination. The same procedures as described in the first visit will be done.
Follow up - We will obtain contact information (phone number) from all enrolled women. A trained research midwife will be responsible for making phone calls, as well as performing household visits at pre-specified intervals for immediate and early identification of the pregnancy outcome. A team of CHWs will perform home visits to the baby at post-natal day 1 and 6 and questions related to delayed cry, neonatal sepsis and hospital course (if any) will be collected and the weight and length of the baby will be recorded.
Verbal autopsy - The VA team will visit the family after the grieving period (at least 14 days after the death). VA will be performed using a structured tool (http://www.who.int/healthinfo/statistics/WHO_VA_2012_RC1_Instrument.pdf ).
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Pregnant women between 22-34 weeks who reside in Ibrahim Hyderi Goth which is a peri-urban settlement of approximately 70,000 on the south east of Karachi. It is one of the seven union councils in Bin Qasim town which has a population of one million.
Key inclusion criteria (3 listed)
- Pregnant woman coming to the ultrasound clinic between 22-34 weeks of gestation.
- Written informed consent
- Resident of the study area
Key exclusion criteria (4 listed)
- Multiple gestation
- Known congenital anomaly in the fetus or newborn
- Refusal for the ultrasound
- Poor echocardiographic images for Doppler acquisition
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Stillbirth
Time frame: At birth
Baby born with no signs of life at or after 28 weeks of gestation
Early neonatal mortality
Time frame: Within the first 7 days of life
Death of a baby within the first 7 days of life
5 secondary outcomes
IUGR
Time frame: At birth
Prematurity
Time frame: At birth
Birth asphyxia
Time frame: At birth
Neonatal sepsis
Time frame: Within the first 7 days of life
Low Birth Weight
Time frame: At birth
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Jan 2018.
- Individual participant dataSharing planned: Undecided
Related trials for Perinatal Mortality
Recruiting
Amnioinfusion's Protective Effects on Respiratory and Longitudinal Pediatric Outcomes After Intrapartum Meconium Exposure
Neonatal Respiratory Distress Related Conditions, Meconium
Active, not recruiting
Well-Mama Community Doula Navigator Study
Pregnancy Related
Enrolling by invitation
Pregnancy in the Context of Urbanicity and Climate Change. The Overall Aim of the Project is to Co-create, Implement, and Test New Clinical Guidelines in Order to Improve the Quality of Care in Antenatal Clinics in the Context of Urbanisation and Climate Change in Dar es Salaam, Tanzania.
Perinatal Death, Hypertension, Pregnancy-Induced
Not yet recruiting
Perinatal Mortality Outcomes Through Household Infection Pathways
Stillbirth and Neonatal Mortality, Perinatal Mortality
RecruitingObservational study
Optimization of Routine Obstetric and Neonatal Care in the Management of Severe Perinatal Asphyxia in Term or Near-term Newborns: Analysis of Sub-optimal Care
Perinatal Asphyxia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Questions about this trial
What is this clinical trial studying?
An observational study of Perinatal Mortality and Neonatal Morbidities, run by Aga Khan University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 12 Jan 2018. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Zahra Hoodbhoy (92-21-34930051 ext. 4126, zahra.hoodbhoy@aku.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Stillbirth (time frame: At birth). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jan 2018.